Marianne P. Allen

Array ( [id] => 11018097 [patent_doc_number] => 20160215049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/974908 [patent_app_country] => US [patent_app_date] => 2015-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 163 [patent_figures_cnt] => 163 [patent_no_of_words] => 129422 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14974908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714389 [patent_doc_number] => 20170368149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => METHODS FOR INCREASING SERUM IGF-1 IN AN ANIMAL [patent_app_type] => utility [patent_app_number] => 15/535781 [patent_app_country] => US [patent_app_date] => 2015-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15535781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10805291 [patent_doc_number] => 20160151448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'MULTIMERIC TIE 2 AGONISTS AND USES THEREOF IN STIMULATING ANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 14/970128 [patent_app_country] => US [patent_app_date] => 2015-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 21547 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14970128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428031 [patent_doc_number] => 20180265558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => MODIFIED FIBROBLAST GROWTH FACTOR 1 (FGF-1) POLYPEPTIDES WITH INCREASED BINDING AFFINITY FOR HEPARIN AND ASSOCIATED METHODS [patent_app_type] => utility [patent_app_number] => 15/532843 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15532843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11002539 [patent_doc_number] => 20160199488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-14 [patent_title] => 'Combination therapy for neoplasia treatment' [patent_app_type] => utility [patent_app_number] => 14/946067 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 10021 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14946067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10805331 [patent_doc_number] => 20160151487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'FCRN-BINDING ABOLISHED ANTI-IGF-1R ANTIBODIES AND THEIR USE IN THE TREATMENT OF VASCULAR EYE DISEASES' [patent_app_type] => utility [patent_app_number] => 14/926982 [patent_app_country] => US [patent_app_date] => 2015-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 54994 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14926982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11937830 [patent_doc_number] => 20170241980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Assay for FGF2 Secretion and Signaling' [patent_app_type] => utility [patent_app_number] => 15/510177 [patent_app_country] => US [patent_app_date] => 2015-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 3714 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15510177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678079 [patent_doc_number] => 20160024224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'ANTI-FACTOR B ANTIBODIES AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 14/876655 [patent_app_country] => US [patent_app_date] => 2015-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17640 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14876655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784185 [patent_doc_number] => 20160130340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'DOSING REGIMENS USING ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF RHEUMATOID AND PSORIATIC ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 14/876376 [patent_app_country] => US [patent_app_date] => 2015-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 81323 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14876376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14119321 [patent_doc_number] => 10246507 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-02 [patent_title] => Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same [patent_app_type] => utility [patent_app_number] => 14/869636 [patent_app_country] => US [patent_app_date] => 2015-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 18814 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14869636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13024429 [patent_doc_number] => 10034826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Peptides and their use in the treatment of skin [patent_app_type] => utility [patent_app_number] => 14/844095 [patent_app_country] => US [patent_app_date] => 2015-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8857 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14844095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476160 [patent_doc_number] => 20150361177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS' [patent_app_type] => utility [patent_app_number] => 14/839695 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 22743 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14839695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13968303 [patent_doc_number] => 10213485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => HGF preparation suitable for treatment of neurological disorders [patent_app_type] => utility [patent_app_number] => 15/507886 [patent_app_country] => US [patent_app_date] => 2015-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11094 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 232 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15507886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11678330 [patent_doc_number] => 09676846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-13 [patent_title] => 'Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II' [patent_app_type] => utility [patent_app_number] => 14/832803 [patent_app_country] => US [patent_app_date] => 2015-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 36 [patent_no_of_words] => 37001 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14832803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10468602 [patent_doc_number] => 20150353618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-10 [patent_title] => 'Methods and Pharmaceutical Composition for the Preservation of Vascular Endothelial Cell Barrier Integrity' [patent_app_type] => utility [patent_app_number] => 14/823636 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17104 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14823636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11901993 [patent_doc_number] => 09771417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-26 [patent_title] => 'Angiopoietin-like 4 antibodies and methods of use' [patent_app_type] => utility [patent_app_number] => 14/819680 [patent_app_country] => US [patent_app_date] => 2015-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 38412 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14819680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15306493 [patent_doc_number] => 10517928 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Pharmaceutical composition for treating and/or preventing esophageal stenosis [patent_app_type] => utility [patent_app_number] => 15/503078 [patent_app_country] => US [patent_app_date] => 2015-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 3373 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10988919 [patent_doc_number] => 20160185864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'METHODS OF TREATING FGFR3 RELATED CONDITIONS' [patent_app_type] => utility [patent_app_number] => 14/813669 [patent_app_country] => US [patent_app_date] => 2015-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 43506 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14813669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16052825 [patent_doc_number] => 20200188267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => HUMAN FIBROBLAST GROWTH FACTOR-2 MUTANT WITH INCREASED STABILITY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/579235 [patent_app_country] => US [patent_app_date] => 2015-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11113591 [patent_doc_number] => 20160310563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'Methods for Treating Diabetic Wounds' [patent_app_type] => utility [patent_app_number] => 14/805618 [patent_app_country] => US [patent_app_date] => 2015-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 27537 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14805618 [rel_patent_id] =>[rel_patent_doc_number] =>)